Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.67 |
| ▸ | ACACA | Q13085 | 13/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | MST1R | Q04912 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14345718 | 0.90 | ACACB (0.55) | ACACBACACAGSK3BJAK2NTRK1 | |
| SCHEMBL6113587 | 0.89 | ACACB (0.61) | ACACBACACAGSK3BJAK2NTRK1 | |
| SCHEMBL4546185 | 0.85 | ACACB (0.50) | ACACBACACAGSK3BRECQLPGR | |
| SCHEMBL4546190 | 0.83 | ACACB (0.48) | ACACBACACARECQL | |
| SCHEMBL11941316 | 0.82 | ACACB (0.65) | ACACBACACAGSK3BJAK2NTRK1 | |
| SCHEMBL4546200 | 0.81 | ACACB (0.46) | ACACBACACARECQL | |
| SCHEMBL16080659 | 0.81 | ACACB (1.00) | ACACBACACAGSK3BJAK2NTRK1 | |
| SCHEMBL16043872 | 0.81 | ACACB (1.00) | ACACBACACAGSK3BJAK2NTRK1 | |
| SCHEMBL16043870 | 0.81 | ACACB (1.00) | ACACBACACAGSK3BJAK2NTRK1 | |
| SCHEMBL4546195 | 0.80 | ACACB (0.51) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | claimed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8173697-B2 | Alkoxyalkyl-substituted cyclic keto-enols | BAYER CROPSCIENCE AG (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173697-B2 | Alkoxyalkyl-substituted cyclic keto-enols | BAYER CROPSCIENCE AG (DE) | 2012-05-08 | — | — | US | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-20090298828-A1 | Alkoxyalkyl-Substituted Cyclic Keto-Enols | BAYER CROPSCIENCE AG (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298828-A1 | Alkoxyalkyl-Substituted Cyclic Keto-Enols | BAYER CROPSCIENCE AG (DE) | 2009-12-03 | — | — | US | disclosed |
| WO-2007140881-A1 | ALKOXYALKYL-SUBSTITUTED CYCLIC KETO-ENOLS | BAYER CROPSCIENCE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | ACACB 310/4885ACACA 541/4885GSK3B 685/4885 |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | CYP46A1, LIPC, CYP27A1 | ACACB 85/4885ACACA 90/4885GSK3B 570/4885 |
| US-20090298828-A1 | Alkoxyalkyl-Substituted Cyclic Keto-Enols | DDT, AKR1D1, EBP | ACACB 249/4885ACACA 529/4885GSK3B 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.